Loading...
•
Dec 31, 2024
Viking Therapeutics Q4 2024 Earnings Report
Viking Therapeutics reported its fourth quarter and full-year 2024 financial results, highlighting progress in its clinical pipeline and a strong cash position.
Key Takeaways
Viking Therapeutics announced positive data from four different clinical trials in 2024, including for VK2735 in obesity and VK2809 for MASH. The company ended the year with a strong cash position of $903 million and plans to initiate Phase 3 trials for subcutaneous VK2735 in obesity in 2Q25.
Initiation of Phase 3 studies for subcutaneous VK2735 for obesity is planned for 2Q25.
The Phase 2 VENTURE-Oral Dosing Trial evaluating VK2735 in obesity is currently underway.
Viking Therapeutics reported a strong year-end cash position of $903 million.
The company achieved positive data from four different clinical trials in 2024, including for VK2735 (subcutaneous and oral) and VK2809.
Viking Therapeutics
Viking Therapeutics
Forward Guidance
Viking Therapeutics plans to advance its pipeline programs, including initiating Phase 3 trials for subcutaneous VK2735 in obesity and filing an IND for its DACRA program later this year. The company expects to report data from the VENTURE-Oral Dosing trial in 2H25.
Positive Outlook
- Initiation of Phase 3 studies for subcutaneous VK2735 for obesity planned for 2Q25.
- Phase 2 VENTURE-Oral Dosing Trial evaluating VK2735 in obesity underway, with data expected in 2H25.
- Planning to file an IND application for the Dual Amylin and Calcitonin Receptor Agonist (DACRA) program later this year.
- Strong balance sheet with over $900 million in cash and equivalents to support clinical goals.
- Continued evaluation of potential next steps for VK2809 following positive Phase 2b VOYAGE study results.
Challenges Ahead
- No specific negative forward guidance was provided in the report.
- Potential for unexpected safety or tolerability challenges in ongoing or future trials.
- Regulatory requirements and clinical trial success are subject to risks and uncertainties.
- Prior clinical and preclinical results may not be replicated in future studies.
- The company disclaims any obligation to update forward-looking statements except as required by law.